Estimated Prevalence of Harmful Alcohol Consumption in Pregnant and Nonpregnant Women in Saxony-Anhalt (NorthEast Germany) Using Biomarkers.
Adolescent
Adult
Alcohol Drinking
/ blood
Biomarkers
/ blood
Female
Germany
/ epidemiology
Humans
Middle Aged
Pregnancy
Pregnancy Complications
/ blood
Pregnancy Trimesters
/ blood
Prevalence
Prospective Studies
Retrospective Studies
Transferrin
/ analogs & derivatives
Young Adult
gamma-Glutamyltransferase
/ blood
%CDT
Alcohol
GGT
GGT-CDT Ratio
Pregnancy
Prevalence
Journal
Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
12
10
2020
accepted:
27
01
2021
pubmed:
7
2
2021
medline:
15
12
2021
entrez:
6
2
2021
Statut:
ppublish
Résumé
Alcohol consumption is commonly accepted in Western societies and is a known risk factor in pregnancy, which could lead to fetal alcohol spectrum disorders (FASDs). Prevalence of alcohol consumption during pregnancy is mostly unknown. Prevalence estimates in publications based on questionnaires are limited by possible underreporting due to social stigmatization. The aim of this study was to estimate the prevalence of harmful alcohol consumption in a large cohort of pregnant women using different biomarkers related to alcohol consumption and compare the findings with those of non-pregnant women METHODS: Routine parameters known to be influenced by alcohol consumption (γ-glutamyltransferase, GGT; carbohydrate-deficient transferrin, CDT/%CDT; mean corpuscular/cell volume, MCV; combined parameter of GGT and %CDT, GGT-CDT) were analyzed in serum samples of 2,182 pregnant women and 743 non-pregnant, age-matched females. Data were tested for (i) differences between pregnant and non-pregnant women and (ii) changes across the 3 trimesters of pregnancy. Prevalence rates differ greatly according to the parameter and cutoff, which reflects the limitations of assessing alcohol consumption with biomarkers. The prevalence of harmful alcohol consumption on the basis of a single or several elevated parameters was 13.8% (95% CI: 12.4 to 15.2) in pregnant women and 18.6% (95% CI: 15.8 to 21.4) in non-pregnant women, though 85.0% of the elevated measurements were attributable to an isolated elevation in %CDT only. Using GGT-CDT as the parameter with the highest specificity according to the literature, the estimated prevalence of harmful alcohol consumption in pregnancy is 0.5% (95% CI: 0.2 to 0.7). Estimated prevalence rates differ greatly with respect to the biomarkers and cutoffs used. The use of CDT/%CDT alone appears to overestimate harmful alcohol consumption during pregnancy.
Sections du résumé
BACKGROUND
Alcohol consumption is commonly accepted in Western societies and is a known risk factor in pregnancy, which could lead to fetal alcohol spectrum disorders (FASDs). Prevalence of alcohol consumption during pregnancy is mostly unknown. Prevalence estimates in publications based on questionnaires are limited by possible underreporting due to social stigmatization. The aim of this study was to estimate the prevalence of harmful alcohol consumption in a large cohort of pregnant women using different biomarkers related to alcohol consumption and compare the findings with those of non-pregnant women METHODS: Routine parameters known to be influenced by alcohol consumption (γ-glutamyltransferase, GGT; carbohydrate-deficient transferrin, CDT/%CDT; mean corpuscular/cell volume, MCV; combined parameter of GGT and %CDT, GGT-CDT) were analyzed in serum samples of 2,182 pregnant women and 743 non-pregnant, age-matched females. Data were tested for (i) differences between pregnant and non-pregnant women and (ii) changes across the 3 trimesters of pregnancy.
RESULTS
Prevalence rates differ greatly according to the parameter and cutoff, which reflects the limitations of assessing alcohol consumption with biomarkers. The prevalence of harmful alcohol consumption on the basis of a single or several elevated parameters was 13.8% (95% CI: 12.4 to 15.2) in pregnant women and 18.6% (95% CI: 15.8 to 21.4) in non-pregnant women, though 85.0% of the elevated measurements were attributable to an isolated elevation in %CDT only. Using GGT-CDT as the parameter with the highest specificity according to the literature, the estimated prevalence of harmful alcohol consumption in pregnancy is 0.5% (95% CI: 0.2 to 0.7).
CONCLUSION
Estimated prevalence rates differ greatly with respect to the biomarkers and cutoffs used. The use of CDT/%CDT alone appears to overestimate harmful alcohol consumption during pregnancy.
Substances chimiques
Biomarkers
0
Transferrin
0
carbohydrate-deficient transferrin
0
gamma-Glutamyltransferase
EC 2.3.2.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-827Informations de copyright
© 2021 The Authors. Alcoholism: Clinical & Experimental Research published by Wiley Periodicals LLC on behalf of Research Society on Alcoholism.
Références
Andresen-Streichert H, Müller A, Glahn A, Skopp G, Sterneck M (2018) Alcohol biomarkers in clinical and forensic contexts. Dtsch Arztebl Int 115:309-315.
Atzendorf J, Rauschert C, Seitz NN, Lochbühler K, Kraus L (2019) The use of alcohol, tobacco, illegal drugs and medicines - an estimate of consumption and substance-related disorders in Germany. Dtsch Arztebl Int 116:577-584.
Bakhireva LN, Cano S, Rayburn WF, Savich RD, Leeman L, Anton RF, Savage DD (2012) Advanced gestational age increases serum carbohydrate-deficient transferrin levels in abstinent pregnant women. Alcohol Alcohol 47:683-687.
Bathia S, Drake DM, Miller L, Wells PG (2019) Oxidative stress and DNA damage in the mechanisms of fetal alcohol spectrum disorders. Birth Defects Res 111:714-748.
England LJ, Bennet C, Denny CH, Honein MA, Gilboa SM, Kim SY, Guy GP Jr, Tran EL, Rose CE, Bohm MK, Boyle CA (2020) Alcohol use and co-use of other substances among pregnant females aged 12-44 years - United Stated, 2015-2018. MMWR Morb Mortal Wkly Rep 31:1009-1010.
GBD (2016) Risk Factors Collaborators (2017) Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1345-1422.
Göransson M, Magnusson A, Bergman H, Rydberg U, Heilig M (2003) Fetus at risk: prevalence of alcohol consumption during pregnancy estimated with a simple screening method in Swedish antenatal clinics. Addiction 98:1513-1520.
Hietala J, Koivisto H, Anttila P, Niemelä O (2006) Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol & Alcohol 41:528-533.
Hietala J, Puukka K, Koivisto H, Anttila P, Niemelä O (2005) Serum gamma-glutamyl transferase in alcoholics, moderate drinkers and abstainers: effect of GT reference intervals at population level. Alcohol & Alcohol 40:511-514.
Howlett H, Abernethy S, Brown NW, Rankin J, Gray WK (2017) How strong is the evidence for using blood biomarkers alone to screen for alcohol consumption during pregnancy? A systematic review. Eur J Obstet Gynecol Reprod Biol 213:45-52.
Howlett H, Mackenzie S, Gray WK, Rankin J, Nixon L, Brown NW (2020) Assessing the prevalence of alcohol consumption in early pregnancy using blood biomarker analysis: a consistent pattern across north-east England? J Public Health (Oxf.) 42:e74-e80.
Kenan N, Larsson A, Axelsson O, Helander A (2011) Changes in transferrin glycosylation during pregnancy may lead to false-positive carbohydrate-deficient transferrin (CDT) results in testing for riskful alcohol consumption. Clin Chim Acta 412:129-133.
Kraus L, Seitz NN, Shield KD, Gmel G, Rehm J (2019) Quantifying harms to others due to alcohol consumption in Germany: a register-based study. BMC Med 17:59-67.
Lange S, Probst C, Gmel G, Rehm J, Burd L, Popova S (2017) Global Prevalence of Fetal Alcohol Spectrum Disorder Among Children and Youth. JAMA Pediatr 171:948-956.
Larsson A, Palm M, Hansson L-O, Axelsson O (2008) Reference values for clinical chemistry tests during normal pregnancy. BJOG 115:874-881.
Niemelä S, Niemelä O, Ritvanen A, Gissler M, Bloigu A, Vääräsmäki M, Kajantie E, Werler M, Surcel HM (2016b) Assays of gamma-glutamyl transferase and carbohydrate-deficient transferrin combination from maternal serum improve the detection of prenatal alcohol exposure. Alcohol Clin Exp Res 40:2385-2393.
Niemelä S, Niemelä O, Ritvanen A, Gissler M, Bloigu A, Werler M, Surcel HM (2016a) Fetal alcohol syndrome and maternal alcohol biomarkers in sera: a register-based case-control study. Alcohol Clin Exp Res 40:1507-1514.
Popova S, Lange S, Probst C, Gmel G, Rehm J (2017) Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohols syndrome: a systematic review and meta-analysis. Lancet Glob Health 5:e290-299.
Rissman A, Götz D, Köhn A, Spillner C, Vogt C (2014) Annual Report 2013 of the Federal State of Saxony-Anhalt About Frequency of Congenital Malformations and Anomalies as Well as Genetically Caused Diseases. Available at: http://www.monz.ovgu.de/monz_mm/Dokumente/Jahresberichte/Bericht2013_ENGLISCH.pdf Accessed September 2014 .
Shipton D, Tappin D, Sherwood R, Mactier H, Aitken D, Crossley J (2013) Monitoring population levels of alcohol consumption in pregnant women: a case for using biomarkers. Subst Use Misuse 48:569-573.
Stibler H (1991) Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 37:2029-2037.